Weijian Huang

机构：Northwestern University, Guangxi Medical University, Shanghai Jiao Tong University, Wenzhou Medical University, Renji Hospital, First Affiliated Hospital of Wenzhou Medical University, Shanghai CASB Biotechnology (China), First Affiliated Hospital of GuangXi Medical University, Shanghai Cell Therapy Research Institute, Yulin Orthopedics Hospital of Chinese and Western Medicine · ORCID：0000-0001-8417-7804

发表论文 107 篇 · 总被引 1587 次 · h-index 20

代表论文

• Angiotension II directly bind P2X7 receptor to induce myocardial ferroptosis and remodeling by activating human antigen R (2024 · Redox Biology · 被引 28)
• Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation (2024 · European Heart Journal - Cardiovascular Pharmacotherapy · 被引 24)
• Macrophage OTUD1‐CARD9 axis drives isoproterenol‐induced inflammatory heart remodelling (2024 · Clinical and Translational Medicine · 被引 22)
• Emodin Suppresses NLRP3/GSDMD-induced Inflammation via the TLR4/MyD88/NF-κB Signaling Pathway in Atherosclerosis (2024 · Cardiovascular Drugs and Therapy · 被引 19)
• Integration of ATAC-Seq and RNA-Seq reveals FOSL2 drives human liver progenitor-like cell aging by regulating inflammatory factors (2023 · BMC Genomics · 被引 16)
• The novel GSDMD inhibitor GI‐Y2 exerts antipyroptotic effects to reduce atherosclerosis (2025 · Clinical and Translational Medicine · 被引 11)